

10/528336

CORRECTED VERSION

Rec'd PCT/PTO 18 MAR 2005

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number  
WO 2004/029064 A1

(51) International Patent Classification<sup>7</sup>: C07F 9/6561,  
9/6509, A61K 31/675

(21) International Application Number:  
PCT/KR2003/001932

(22) International Filing Date:  
22 September 2003 (22.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10-2002-0058310  
26 September 2002 (26.09.2002) KR

(71) Applicant (for all designated States except US): LG LIFE  
SCIENCES LTD. [KR/KR]; LG Twin Tower, East Tower,  
20, Yoido-dong, Youngdungpo-ku, 150-010 Seoul (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHOI, Jong-Ryoo  
[KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1,  
Moongi-dong, Yuseong-gu, 305-380 Taejeon (KR).  
HWANG, Jae-Taeg [KR/KR]; R & D Park, LG Life  
Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, 305-380  
Taejeon (KR). CHO, Dong-Gyu [KR/KR]; R & D Park,  
LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu,  
305-380 Taejeon (KR). ROH, Kee-Yoon [KR/KR]; R  
& D Park, LG Life Sciences Ltd., 104-1, Moongi-dong,  
Yuseong-gu, 305-380 Taejeon (KR). KIM, Chun-Hyung  
[KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1,  
Moongi-dong, Yuseong-gu, 305-380 Taejeon (KR). KIM,  
Chung-Mi [KR/KR]; R & D Park, LG Life Sciences Ltd.,  
104-1, Moongi-dong, Yuseong-gu, 305-380 Taejeon (KR).  
HAN, Min-Joon [KR/KR]; R & D Park, LG Life Sciences  
Ltd., 104-1, Moongi-dong, Yuseong-gu, 305-380 Taejeon  
(KR). KIM, Jeong-Min [KR/KR]; R & D Park, LG Life  
Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, 305-380  
Taejeon (KR). CHO, Woo-Young [KR/KR]; R & D Park,

LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu,  
305-380 Taejeon (KR). KIM, Gyoung-Won [KR/KR]; R  
& D Park, LG Life Sciences Ltd., 104-1, Moongi-dong,  
Yuseong-gu, 305-380 Taejeon (KR). Ahn, Sinbyoung  
[KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1,  
Moongi-dong, Yuseong-gu, 305-380 Taejeon (KR).

(74) Agent: CHOI, Kyu-Pal; Halla Classic Building 4F,  
824-11, Yeoksam-dong, Kangnam-ku, 135-080 Seoul  
(KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:  
19 May 2005

(15) Information about Correction:  
see PCT Gazette No. 20/2005 of 19 May 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: (+)-TRANS-ISOMERS OF (1-PHOSPHOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE  
DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL  
AGENTS THEREOF

(57) Abstract: The present invention relates to (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside  
derivatives of the formula (1) which are useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically ac-  
ceptable saltss, hydrates, or solvates thereof, and processes for the preparation of stereoisomers of the compounds of the formula  
(1), and a composition for the treatment of viral diseases (particularly, against hepatitis B virus) comprising (+)-trans-isomer of the  
compound of the formula (1), pharmaceutically acceptable salt, hydrate, or solvate thereof as an active substance.

WO 2004/029064 A1